Therapeutic Workshop
New Therapeutics to Improve CHF Outcomes
Thursday, October 30, 2008
9:30am - 10:45am
Sea Cliff
Congestive heart failure can affect almost anyone; today there are more than five million people in the U.S. diagnosed with CHF. The people most at risk include those who have been diagnosed with coronary artery disease, heart attack, cardiomyopathy, heart valve disease, chronic or untreated hypertension, chronic kidney disease and thyroid dysfunction. Congestive heart failure is most common in elderly people, particularly those over the age of 70, a growing global population. A complicated disease of multiple etiologies, CHF presents significant clinical treatment challenges. This panel will provide an update on products in development to improve CHF outcomes.
Moderator
- Michael G. King, Jr, Managing Director and Director of Research, Rodman & Renshaw, LLC
Panelists
Industry:
- Detlef Albrecht, MD, Chief Medical Officer and Senior Vice President of Drug Development, Relypsa, Inc.
- Michael R. Bristow, MD, PhD, Professor of Medicine in Cardiology, University of Colorado Denver School of Medicine, Co-Director of the University of Colorado Cardiovascular Institute, Chairman and Chief Science and Medical Officer, ARCA biopharma
- Andrew A. Wolff, MD, Chief Medical Officer and Senior Vice President of Clinical Research and Development, Cytokinetics, Inc; Associate Clinical Professor of Medicine, University of California, San Francisco
Clinician:
- Barry Massie, MD, Professor of Medicine at the University of California at San Francisco, Chief Cardiology Division at San Francisco Veterans Affairs Medical Center
- John R. Teerlink, MD; Associate Professor of Medicine, University of California, San Francisco; Director of the Heart Failure Clinic and Director of Clinical Echocardiography, San Francisco Veterans Affairs Medical Center
Who's Who
Michael G. King, Jr Mr. King joined Rodman and Renshaw in May 2005 as a Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw, LLC, a broker-dealer affiliate. In January, 2006, he also became Director of Research. From June 2002 through May 2005, Mr. King was a managing director and senior equity research analyst in the Health Care Group at Banc of America Securities LLC where he covered the biotechnology sector for three years. From September 1998 through June 2002, Mr. King was a managing director and senior biotechnology analyst at Robertson Stephens. He served as a senior biotechnology analyst at Vector Securities from March 1996 through September 1998, and at Dillon, Read & Co. from November 1994 to March 1996. Mr. King received his B.B.A. with honors in finance from Bernard M. Baruch College in 1985. He was ranked 4th for his stock picking accuracy in the Wall Street Journal's annual "Best on the Street" survey in 2001 and 2000 for his coverage of OSI Pharmaceuticals. Michael's coverage of the cardiology/metabolic space includes Cytokinetics, Nile Therapeutics, Cardiome, Pharmacopeia, Amylin and Vivus, among others.
Detlef Albrecht, MD Dr. Albrecht joined Relypsa in October 2007. Previously, he was the Senior Vice President of R&D and Chief Medical Officer at Ilypsa from 2004 to 2007. Before that, Dr. Albrecht held a series of clinical development and medical affairs positions at ALZA Corporation, most recently as Vice President Clinical Development and Member of the Management Board. He started his career in the Pharmaceutical Industry in 1992 with Schwarz Pharma in Germany. From 1997 through August 1999, Dr. Albrecht was Director Clinical Research and Development at Miravant Medical Technologies in Santa Barbara. Dr. Albrecht received his M.D. degree from the Rheinisch Westfaelische Technische Hochschule in Aachen, Germany and c onducted postdoctoral research in the physiology of the urinary tract and sexual dysfunction.
Dr. Michael R. Bristow, MD, PhD Dr. Bristow is the chief science and medical officer of ARCA biopharma, a company he founded with the mission of developing genetically targeted therapies for heart failure and other cardiovascular diseases. He currently serves as Professor of Medicine in Cardiology at the University of Colorado Denver School of Medicine, where he headed the Cardiology Division from 1991 to 2004, and is the Co-Director of the University of Colorado Cardiovascular Institute. Bristow has authored more than 350 peer-reviewed papers and book chapters on heart failure and other cardiovascular diseases. He was the lead investigator for the Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure (COMPANION) trial and has been involved with many other heart failure trials, including the Beta-Blocker Evaluation of Survival Test (BEST).
Andrew A. Wolff, MD Dr. Wolff has been Cytokinetic’s Chief Medical Officer and Senior Vice President of Clinical Research and Development since September 2004. Prior to Cytokinetics, he was at CV Therapeutics from 1994-2004, where he was the Senior Vice President and Chief Medical Officer, as well as holding various positions of increasing responsibility. Before CV Therapeutics, Dr. Wolff held various drug development positions in both the U.S. and the UK for Syntex Corporation. Since 1986, Dr. Wolff has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently an Associate Clinical Professor, and an Attending Cardiologist in the Coronary Care Unit at the San Francisco Veterans Administration Medical Center. Dr. Wolff received a B.A. degree in Chemistry and Biology from the University of Dayton and an M.D. from Washington University Medical School in Saint Louis, Missouri.
Prior to joining ARCA, Bristow was also the principal founder and former chief science and medical officer of Myogen, Inc., a biopharmaceutical company that developed treatments for hypertension. At Myogen, Bristow led a drug discovery research program focused on the development of disease-modifying drugs for the treatment of chronic heart failure and related cardiovascular disorders. Myogen was acquired by Gilead Sciences, Inc., in 2006.
Barry Massie, MD Dr. Massie is a Professor of Medicine at the University of California at San Francisco and also the Chief of Cardiology Division at San Francisco Veterans Affairs Medical Center. Dr. Massie is an expert in the areas of heart failure, hypertension, cardiovascular therapeutics, and is involved in various clinical trials. He has served on the FDA Cardiorenal Advisory Panel for over five years (as Chair for one), and consults frequently on issues of drug development, trial design, preparation for FDA presentations, and related issues.
John Teerlink, MD Dr. Teerlink is an Associate Professor of Medicine at the University of California, San Francisco and is also Director of the Heart Failure Clinic and Director of Clinical Echocardiography at the San Francisco Veterans Affairs Medical Center. Dr. Teerlink has expertise in the treatment of acute and chronic heart failure and in the design, execution and interpretation of clinical trials in these fields. His clinical interests include the role of renal disease in heart failure, with basic science research interests in the role of neurohormones and cytokines in the evolution of ventricular remodeling and heart failure, including TGFbeta and endothelin. Dr. Teerlink was recently a member of the Food & Drug Administration's Cardiovascular and Renal Drugs Advisory Committee.